Raltegravir in Patients With End Stage Liver Disease and in Transplant Recipients
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
This phase I/II, multi-center study is designed to determine the pharmacokinetic profile of
Raltegravir in patients with end stage liver disease and to assess drug-drug interaction when
Raltegravir is combined with immunosuppressive therapy in liver transplant recipients.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
ANRS, Emerging Infectious Diseases French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)